ADDvise receives order worth EUR 2.1 million

16-01-2024   Regulatory press release

ADDvise Group’s subsidiary Labplan has received an order from the pharmaceutical company Eli Lilly.

The order is worth approximately EUR 2.1 million and involves advanced laboratory instruments for quality control purposes. The instruments will be used in a new manufacturing facility for biologic pharmaceuticals in Limerick, Ireland. Delivery of the order is scheduled to the fourth quarter 2024.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71

Important information

This information is information that ADDvise Group AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on January 16, 2024 at 07.30 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business - both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB is the Company's Certified Adviser. Additional information is available at